Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CA-170 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CA-170 | EXPERIMENTAL | Taken orally in a once or twice daily schedule. |
| Name | Type | Description |
|---|---|---|
| CA-170 | DRUG | Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma. Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer. |
Inclusion Criteria: 1. Males and females ≥ 18 years of age; 2. Life expectancy of at least 3 months; 3. ECOG PS ≤ 1; 4. Acceptable bone marrow and organ function at screening; 5. Ability to swallow and retain oral medications; 6. Negative serum pregnancy test in women of childbearing potential; 7. ...
CA-170 is an investigational oral small molecule being studied for the treatment of advanced solid tumors or lymphomas. It is a checkpoint antagonist designed to target PD-L1, PD-L2, and VISTA pathways. The drug is currently in clinical development and is not approved by regulatory authorities.
CA-170 targets PD-L1, PD-L2, and VISTA, which are immune checkpoint proteins involved in tumor evasion. By antagonizing these targets, CA-170 aims to enhance the body's immune response against cancer cells. This mechanism is being evaluated in patients with advanced solid tumors or lymphomas.
CA-170 is being developed by Curis, Inc., a biotechnology company traded on NASDAQ under the ticker symbol CRIS. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug in oncology.
CA-170 is in Phase 1 clinical development. It has completed a Phase 1 trial in patients with advanced solid tumors or lymphomas. The drug remains investigational and has not received FDA approval for any indication.
CA-170 has been studied in one clinical trial, NCT02812875, titled "A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas." This Phase 1 trial enrolled 71 participants and was conducted in the United States, South Korea, Spain, and the United Kingdom.
CA-170 is a checkpoint antagonist that targets PD-L1, PD-L2, and VISTA. While it acts on PD-L1, it is distinct from monoclonal antibody PD-L1 inhibitors because it is an oral small molecule. Its broader targeting of multiple checkpoints differentiates it from single-target agents.